![]() Oxurion Oxurion (formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. | ![]() Aerie Pharmaceuticals Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. | ![]() ANI Pharmaceuticals ANI Pharmaceuticals develops, manufactures and markets top quality prescription pharmaceuticals, made in the U.S.A. | |
Founding Date | Founding Date 1991 | Founding Date 2005 | Founding Date 1996 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Leuven, BE HQ Dublin 8, IE | Locations Irvine, US HQ Dublin, IE 千代田区, JP Henley On Thames, GB Bedminster, US Durham, US | Locations Baudette, US HQ Oakville, CA Baudette, US |
Employees | Employees 785% increase | Employees 3808% increase | Employees 33813% increase |
Valuation ($) | Valuation ($) 626.1 k | Valuation ($) 722.2 m | Valuation ($) 1.2 b |
Financial | |||
Revenue (est.) | Revenue (est.) €555k (FY, 2025) | Revenue (est.) $194.1m (FY, 2021) | Revenue (est.) $883.4m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $26.8m (FY, 2021) | Cost of goods N/A |
Net income | Net income (€3.7m) (FY, 2025) | Net income ($74.8m) (FY, 2021) | Net income N/A |
Funding | |||
Total funding raised | Total funding raised $ 3.9m | Total funding raised $ 388.6m | Total funding raised N/A |

Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.
View company
ANI Pharmaceuticals develops, manufactures and markets top quality prescription pharmaceuticals, made in the U.S.A.
View company